MammoAlert™ app for iPhone and iPad

MammoAlert™ by POC Medical Systems Inc. is an application that complements the Pandora CDx™ digital device developed for the early screening of breast cancer. The results from the MammoAlert™ are delivered via any mobile device and can be stored in a cloud. The application and technology allows for a physician to access the patient testing results from any remote location and is not necessary for them to be present at the screening site.

The application is used to run the MammoAlert™ which is a multiplex disc that can test for 12 patients at a single time. The test itself takes 15 minutes from the time of sample application onto the disc till the time of completion with results available in a digital format. The application allows for the results to be saved onto the device, uploaded into the cloud and printed. The MammoAlert™ application is designed for use by doctors, technicians and administrators who perform the test.

The MammoAlert™application allows for several thousands of patients to be registered before the data can be transferred and stored in the cloud. The application allows for all patient details to be inputted and stored in the cloud, which can be downloaded at any point of time by a physician. It is a simple-to-use application and does not require any trained technician to input data, perform the finger stick test and run the application. This application has been designed so that, it can provide a step-by-step guide for early screening of breast cancer. The MammoAlert™ application works in parallel from the time the actual finger prick on a patient is performed till the test results are obtained, The application has superior features, such as QR code readability that helps to scan each patient whose relevant data can be retrieved as needed. It also helps to control the actual run of the disc in the Pandora CDx™ instrument and displays color coded results in an easy-to-. understand graphical format. The colors are indicative of whether the patient is at a low, medium or high risk which allows for follow-up to be administered immediately.